bendroflumethiazide has been researched along with tacrolimus in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bachmann, S; Conley, J; Ellison, DH; Fürstenberg, A; Hoorn, EJ; Howie, AJ; McCormick, JA; Paliege, A; Roeschel, T; Unwin, RJ; Walsh, SB; Yang, CL | 1 |
1 review(s) available for bendroflumethiazide and tacrolimus
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for bendroflumethiazide and tacrolimus
Article | Year |
---|---|
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
Topics: Analysis of Variance; Animals; Bendroflumethiazide; Calcineurin Inhibitors; Calcium; Cell Line; Chlorides; Creatinine; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Humans; Hydrochlorothiazide; Hypertension; Immunoblotting; Immunohistochemistry; Kidney; Mice; Mice, Knockout; Sodium Chloride Symporters; Tacrolimus | 2011 |